These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29882448)

  • 41. Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: toxicity analysis.
    Zilli T; Jorcano S; Peguret N; Caparrotti F; Hidalgo A; Khan HG; Vees H; Weber DC; Miralbell R
    Acta Oncol; 2014 Jan; 53(1):96-102. PubMed ID: 24032443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?
    Kountouri M; Zilli T; Rouzaud M; Dubouloz A; Linero D; Escudé L; Jorcano S; Miralbell R
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):272-9. PubMed ID: 26853336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Moderate hypofractionated radiotherapy vs conventional fractionated radiotherapy in localized prostate cancer: a systemic review and meta-analysis from Phase III randomized trials.
    Yin Z; You J; Wang Y; Zhao J; Jiang S; Zhang X; Wang P; Tao Z; Wang X; Yuan Z
    Onco Targets Ther; 2019; 12():1259-1268. PubMed ID: 30863093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Outcomes of Hydrogel Spacer Injection Space OAR in Men Submitted to Hypofractionated Radiotherapy for Prostate Cancer.
    Pepe P; Tamburo M; Pennisi M; Marletta D; Marletta F
    In Vivo; 2021; 35(6):3385-3389. PubMed ID: 34697173
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy.
    Feng M; Hanlon AL; Pisansky TM; Kuban D; Catton CN; Michalski JM; Zelefsky MJ; Kupelian PA; Pollack A; Kestin LL; Valicenti RK; DeWeese TL; Sandler HM
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1417-23. PubMed ID: 17418972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
    Madsen BL; Hsi RA; Pham HT; Fowler JF; Esagui L; Corman J
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1099-105. PubMed ID: 17336216
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Acute and Late Rectal Toxicity Following Hypofractionated Radiotherapy in Patients With Prostate Cancer: Results of a Prospective Study.
    Kounadis G; Syrigos N; Kougioumtzopoulou A; Bamias G; Kotteas I; Papatheodoridis G; Grapsa D
    In Vivo; 2022; 36(4):1875-1880. PubMed ID: 35738620
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Twice- vs. thrice-weekly moderate hypofractionated radiotherapy for prostate cancer: does overall treatment time matter?
    Achard V; Jorcano S; Rouzaud M; Escudé L; Miralbell R; Zilli T
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1581-1588. PubMed ID: 30887155
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessing the toxicity after moderately hypofractionated prostate and whole pelvis radiotherapy compared to conventional fractionation.
    Moll M; Goldner G
    Strahlenther Onkol; 2024 Mar; 200(3):188-194. PubMed ID: 37341774
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acute and late toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated pelvic radiation therapy.
    Faria S; Ruo R; Cury F; Duclos M; Souhami L
    Pract Radiat Oncol; 2017; 7(4):264-269. PubMed ID: 28222995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
    Jani AB; Gratzle J
    Urology; 2005 Sep; 66(3):566-70. PubMed ID: 16140079
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Acute and late genitourinary toxicity of conformal radiotherapy for prostate cancer.
    Yoshimura R; Iwata M; Shibuya H; Sakai Y; Kihara K
    Radiat Med; 2006 Oct; 24(8):553-9. PubMed ID: 17041791
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
    Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intensity-modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity.
    Jani AB; Su A; Milano MT
    Urology; 2006 Jan; 67(1):147-51. PubMed ID: 16413351
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study.
    Zilli T; Jorcano S; Rouzaud M; Dipasquale G; Nouet P; Toscas JI; Casanova N; Wang H; Escudé L; Mollà M; Linero D; Weber DC; Miralbell R
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):382-9. PubMed ID: 20884129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fractionated high-dose-rate brachytherapy as monotherapy in prostate cancer: Does implant displacement and its correction influence acute and late toxicity?
    Aluwini S; Busser WM; Baartman LE; Bhawanie A; Alemayehu WG; Boormans JL; Kolkman-Deurloo IK
    Brachytherapy; 2016; 15(6):707-713. PubMed ID: 27364871
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
    Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
    Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.